The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
13 / 176
Overall Ranking
102 / 4724
Industry
Pharmaceuticals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
20
analysts
Buy
Current Rating
191.789
Target Price
+29.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. It is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 17.60.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.
Undervalued
The company’s latest PE is 25.47, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 434.35M shares, decreasing 0.36% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 41.69M shares of this stock.
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. It is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).